Jasper Therapeutics
Develops complement inhibitors and targeted antibodies for immunological disorders.
Something off on this page? Send us feedback.
Profile
Develops complement and antibody therapies for immunologically driven disorders through an acquired-or-licensed-asset model, outsourced clinical and manufacturing infrastructure, and licensing transactions; it has no approved commercial product.
Develops acquired and licensed antibodies and complement therapies for immunologically driven disorders. The current portfolio centers on KP-104, a bifunctional complement inhibitor in a clinical trial for rare renal disorders; briquilimab, an anti-KIT antibody being advanced toward regulatory discussion for SCID conditioning; and preclinical KP-701 for B-cell and autoantibody-mediated disease.
Operates by assembling externally originated or acquired drug assets and developing them through outsourced clinical and manufacturing infrastructure. A China subsidiary supports KP-104 trial execution, while KP-301 and KP-402 are licensed to Mirador for upfront and potential milestone economics.
Has no approved commercial product. Progress depends on clinical results and regulatory review, third-party execution, briquilimab licensing obligations, continued financing, and integration of the Kira acquisition.
Company facts
Key statistics
Year to date −62.3% · Average volume (30d) 784.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 12, 2026 | Piper Sandler | Initiate | Overweight | $2 | ||
| May 15, 2026 | RBC Capital | Reiterate | Sector Perform | $48 | $3 | |
| May 15, 2026 | TD Cowen | Downgrade | Buy | Hold | ||
| Jul 8, 2025 | BMO Capital | Downgrade | Outperform | Market Perform | ||
| Jul 7, 2025 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | −$0.27 | −$0.10 | +62.7% | — | — | — | −8.46% |
| Aug 13, 2026Q2 FY26 | −$0.27 | −$0.10 | +62.7% | — | — | — | +4.76% |
| May 14, 2026Q1 FY26 | −$0.46 | −$0.38 | +17.4% | — | — | — | −11.36% |
| Mar 30, 2026Q4 FY25 | −$0.79 | −$0.32 | +59.5% | — | — | — | −2.64% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$21.0K | $0 | |
| Operating income | −$21.8M | −$27.1M | −$19.2M | −$15.8M | −$11.0M | −$9.2M | |
| Net income | −$21.2M | −$26.7M | −$18.7M | −$9.1M | −$1.2M | −$2.8M | |
| Diluted EPS | −$1.41 | −$1.74 | −$1.13 | −$0.32 | −$0.04 | −$0.10 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $7.3M · Total debt $270.0K · Total assets $11.8M · Shareholders' equity $1.4M
Dividends
No dividends on record.
Ownership
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 16.25M · Float 13.78M · 84.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Velan Capital Master Fund LP | 3.04M | 8.90% | 13G | Aug 17, 2026 |
| T. Rowe Price Investment Management, Inc. | 2.06M | 7.10% | 13G | Nov 14, 2025 |
| Integrated Core Strategies (US) LLC | 1.62M | 5.80% | 13G | Feb 25, 2026 |
| Millennium Management LLC | 1.62M | 9.95% | 13F | May 15, 2026 |
| Acorn Capital Advisors, LLC | 1.41M | 8.68% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 20, 2026 | Matthew E. Ros | officer: Chief Operating Officer | +881 | |
| Jul 20, 2026 | Patrick J. Crutcher | director | +888 | |
| Sep 22, 2025 | Judith Anne Shizuru | director | +82,000 | $2.68 |
| Sep 22, 2025 | Ron Martell | director, officer: President and CEO | +82,000 | $2.68 |
| Sep 22, 2025 | Svetlana Lucas | director | +40,000 | $2.68 |
Peers
- AstraZeneca (ADR)
Marketed PNH complement franchise across C5 blockade and add-on therapy.
- Novartis (ADR)
Spans PNH, renal complement disease and chronic urticaria.
- Sanofi (ADR)
Marketed CSU biologic and Blueprint-derived KIT portfolio.
- Celldex Therapeutics
Closest anti-KIT antibody rival in late-stage chronic urticaria.
- Novo Nordisk (ADR)
Acquired MASP-3 program targets PNH and complement-mediated kidney disease.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Jasper Therapeutics | $0.7140 | +3.02% | $11.4M | — | — | — | — |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Celldex Therapeutics | $39.12 | +0.08% | $2.60B | — | — | 23,240.9 | −97.0% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Median | 23.8 | 16.4 | 4.1 | +0.9% |